← HDFC Mutual Fund

HDFC Pharma and Healthcare Fund - Growth Option - Direct Plan

Equity Data as of Apr 2026 Comparing Feb 2026 → Apr 2026
Share: WhatsApp X
Stocks Held
31
Apr 2026
Equity Holdings
₹2,100.19 Cr
Equity only, excl. debt & cash
Top 5 Weight
34.7%
Moderate
Top 10 Weight
58.0%
Moderate
Changes
33
4 new · 2 exits
Top Sector
Pharmaceuticals & Biotechnology
70.1% of portfolio
📋 What Happened This Month HDFC Pharma and Healthcare Fund made 4 new additions and exited 2 stocks this month. The biggest new buy was Cipla Limited (Pharmaceuticals & Biotechnology) at 4.27% weight. Dr. Lal Path Labs Limited was the biggest exit (Healthcare Services), which was held at 1.63%. Among existing holdings, Acutaas Chemicals Ltd saw the biggest increase — now at 4.07% of the portfolio. Sun Pharmaceutical Industries Limited was trimmed the most, now at 8.05%. Divi's Laboratories Limited remains the top holding with Pharmaceuticals & Biotechnology the dominant sector at 70.1%. ↓ Scroll down for full holdings, sector allocation and month-on-month changes in detail.
Sector Shift Industry allocation month-over-month
Earlier shift unavailable
Needs 3 months of holdings data.
Feb 2026 Apr 2026
Sector Prev Curr Delta
Pharmaceuticals & Biotechnology 68.5% 70.1% +1.6%
Healthcare Services 29.1% 26.6% -2.5%
Healthcare Equipment & Supplies 0.6% 0.6% 0.0%
🟢
Biggest New Buy
Cipla Limited
4.27% weight · Pharmaceuticals & Biotechnology
🔴
Biggest Exit
Dr. Lal Path Labs Limited
1.63% was held · Healthcare Services
Biggest Add
Acutaas Chemicals Ltd
+0.47% · now 4.07%
Biggest Trim
Sun Pharmaceutical Industries Limited
-1.76% · now 8.05%
🤝 Other funds also bought this month
Cipla Limited 65 funds
Cipla Limited
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Bandhan Healthcare Fund - Direct Plan - Growth
Mirae Asset Nifty 500 Healthcare ETF + more
Cohance Lifesciences Limited 32 funds
Cohance Lifesciences Limited
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
ICICI Prudential MNC Fund - Direct Plan - Growth Option
Axis Nifty Smallcap 50 Index Fund - Direct Plan - Growth Option + more
Neuland Laboratories Limited 24 funds
Neuland Laboratories Limited
PGIM India Healthcare Fund - Direct Plan - Growth Option
ITI Business Cycle Fund- Direct Plan- Growth
Abakkus Small Cap Fund - Direct Plan - Growth + more
Novartis India Limited 1 fund
Novartis India Limited
Bandhan BSE Healthcare Index Fund Direct Plan - Growth
👋 Other funds also exited
Corona Remedies Limited 3 funds
Corona Remedies Limited
ICICI Prudential Quality Fund - Direct Plan - Growth
Franklin India Large & Mid Cap Fund - Direct - Growth
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH
Dr. Lal Path Labs Limited 3 funds
Dr. Lal Path Labs Limited
Sundaram Large and Midcap Fund Direct Plan - Growth
UTI Nifty Private Bank Index Fund - Direct Plan - Growth Option
ICICI Prudential Multi-Asset Fund - Direct Plan - Growth

What Changed?

Comparing Feb 2026 → Apr 2026

Feb 2026 Apr 2026
🟢 4 New Entries 🔴 2 Exits ↑ 9 Increased ↓ 18 Decreased
#StockSectorWeight (Apr 2026)
1
Cipla Limited
₹92.18 Cr
Pharmaceuticals & Biotechnology 4.27%
2
Neuland Laboratories Limited
₹42.49 Cr
Pharmaceuticals & Biotechnology 1.97%
3
Cohance Lifesciences Limited
₹12.08 Cr
Pharmaceuticals & Biotechnology 0.56%
4
Novartis India Limited
₹2.12 Cr
Pharmaceuticals & Biotechnology 0.10%
#StockSectorLast Weight (Feb 2026)
1
Dr. Lal Path Labs Limited
₹33.03 Cr
Healthcare Services 1.63%
2
Corona Remedies Limited
₹11.21 Cr
Pharmaceuticals & Biotechnology 0.55%
#StockSectorFeb 2026Apr 2026Change
1
Acutaas Chemicals Ltd
₹87.94 Cr
Pharmaceuticals & Biotechnology 3.60% 4.07% +0.47%
2
Global Health Limited
₹47.70 Cr
Healthcare Services 1.84% 2.21% +0.37%
3
Shilpa Medicare Ltd
₹43.95 Cr
Pharmaceuticals & Biotechnology 1.68% 2.04% +0.36%
4
Vijaya Diagnostic Centre Limited
₹55.14 Cr
Healthcare Services 2.30% 2.55% +0.25%
5
Rubicon Research Limited
₹30.77 Cr
Pharmaceuticals & Biotechnology 1.22% 1.43% +0.21%
6
Divi's Laboratories Limited
₹184.73 Cr
Pharmaceuticals & Biotechnology 8.38% 8.56% +0.18%
7
Anthem Biosciences Limited
₹98.18 Cr
Pharmaceuticals & Biotechnology 4.46% 4.55% +0.09%
8
Aster DM Healthcare Limited
₹117.85 Cr
Healthcare Services 5.42% 5.46% +0.04%
9
Jubilant Pharmova Limited
₹29.43 Cr
Pharmaceuticals & Biotechnology 1.35% 1.36% +0.01%
#StockSectorFeb 2026Apr 2026Change
1
Sun Pharmaceutical Industries Limited
₹173.79 Cr
Pharmaceuticals & Biotechnology 9.81% 8.05% -1.76%
2
Alkem Laboratories Limited
₹101.25 Cr
Pharmaceuticals & Biotechnology 6.21% 4.69% -1.52%
3
Eris Lifesciences Limited
₹35.89 Cr
Pharmaceuticals & Biotechnology 2.28% 1.66% -0.62%
4
Krishna Institute Of Medical Sciences Limited
₹65.65 Cr
Healthcare Services 3.61% 3.04% -0.57%
5
Glenmark Pharmaceuticals Limited
₹130.86 Cr
Pharmaceuticals & Biotechnology 6.62% 6.06% -0.56%
6
Max Healthcare Institute Limited
₹127.97 Cr
Healthcare Services 6.36% 5.93% -0.43%
7
IPCA Laboratories Limited
₹94.66 Cr
Pharmaceuticals & Biotechnology 4.80% 4.39% -0.41%
8
Lupin Limited
₹131.00 Cr
Pharmaceuticals & Biotechnology 6.44% 6.07% -0.37%
9
Fortis Healthcare Limited
₹80.01 Cr
Healthcare Services 4.02% 3.71% -0.31%
10
Sai Life Sciences Limited
₹38.71 Cr
Pharmaceuticals & Biotechnology 2.09% 1.79% -0.30%

Full Portfolio

31 stocks — Apr 2026

# Stock Sector Cap Weight & Value
1
₹184.73 Cr
Pharmaceuticals & Biotechnology
8.56%
2
₹173.79 Cr
Pharmaceuticals & Biotechnology
8.05%
3
₹131.00 Cr
Pharmaceuticals & Biotechnology
6.07%
4
₹130.86 Cr
Pharmaceuticals & Biotechnology
6.06%
5
₹127.97 Cr
Healthcare Services
5.93%
6
₹117.85 Cr
Healthcare Services
5.46%
7
₹101.25 Cr
Pharmaceuticals & Biotechnology
4.69%
8
₹98.18 Cr
Pharmaceuticals & Biotechnology
4.55%
9
₹94.66 Cr
Pharmaceuticals & Biotechnology
4.39%
10
₹92.18 Cr
Pharmaceuticals & Biotechnology
4.27%
🏆 Top stocks held by Equity funds
See which stocks all active Equity fund managers are buying — ranked by total value invested
🏦 HDFC Mutual Fund — Portfolio & Holdings
See all funds managed by HDFC Mutual Fund — conviction stocks, monthly entries & exits

Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.

Found a discrepancy or have feedback? Contact Us — we read every message personally.